Iravani Saadi Mahdiyar, Arandi Nargess, Yaghobi Ramin, Azarpira Negar, Geramizadeh Bita, Ramzi Mani
1Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
2Shiraz Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Indian J Hematol Blood Transfus. 2019 Jul;35(3):446-450. doi: 10.1007/s12288-018-01066-6. Epub 2019 Jan 21.
Recently, dysregulated expression of various micro RNAs has been reported in hematologic malignancies, especially AML disease which affects normal hematopoiesis in these patients and thereby contribute to clinical outcome of AML patients, associated with either poor or favorable prognosis. Herein, we evaluated the expression of miR-181b and miR-222 in acute myeloid leukemia patients and correlation with response to therapy after hematopoietic stem cell transplantation. Eighty newly diagnosed AML patients and 80 healthy controls were recruited. The expression of miR-181b and miR-222 was evaluated by real-time SYBR Green PCR method. miR-181b gene expression was significantly increased (4.7 fold) whereas miR-222 was decreased (18.3 fold) in AML patients compared to controls ( = 0.03 and < 0.001, respectively). Both miR-181b and miR-222 were not associated with response to treatment ( > 0.05). Also, miR-181b and miR-222 were not differentially expressed in AML patients with M3 compared to non-M3 FAB subtypes ( > 0.05). miR-181b and miR-222 are aberrantly expressed in AML patients and their baseline level is not associated with response to treatment.
最近，已有报道称各种微小RNA的表达失调存在于血液系统恶性肿瘤中，尤其是急性髓系白血病（AML），这种疾病会影响这些患者的正常造血功能，进而影响AML患者的临床结局，与预后不良或良好相关。在此，我们评估了急性髓系白血病患者中miR-181b和miR-222的表达及其与造血干细胞移植后治疗反应的相关性。招募了80例新诊断的AML患者和80名健康对照。采用实时SYBR Green PCR法评估miR-181b和miR-222的表达。与对照组相比，AML患者中miR-181b基因表达显著增加（4.7倍），而miR-222表达降低（18.3倍）（分别为=0.03和<0.001）。miR-181b和miR-222均与治疗反应无关（>0.05）。此外，与非M3 FAB亚型的AML患者相比，M3型AML患者中miR-181b和miR-222无差异表达（>0.05）。miR-181b和miR-222在AML患者中异常表达，其基线水平与治疗反应无关。
